Apyx Medical Corp(APYX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Apyx Medical Corp (APYX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores APYX at 27.6/100 on a 32-signal composite quality model, placing it at rank #2,575 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (7.2) and revenue scale (10.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Apyx Medical Corp reports quarterly revenue of $13.9M, net income of $-3.2M, free cash flow of $-3.6M. Top institutional holders of APYX by reported 13-F value include ROYCE & ASSOCIATES, Nantahala Capital Management, Archon Capital Management, based on the most recent SEC filings. APYX trades on the Nasdaq exchange and files with the SEC under CIK 719135. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apyx Medical Corp directly from SEC EDGAR.